Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Salarius Pharmaceuticals, Inc is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 7 staff and has a trailing 12-month revenue of around USD$4.8 million.
|Latest market close||USD$1.08|
|52-week range||USD$0.5552 - USD$4.98|
|50-day moving average||USD$0.7604|
|200-day moving average||USD$1.0411|
|Wall St. target price||USD$4.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-176.437|
|1 week (2021-01-07)||-0.92%|
|1 month (2020-12-15)||28.88%|
|3 months (2020-10-15)||27.66%|
|6 months (2020-07-15)||-25.00%|
|1 year (2020-01-15)||-64.71%|
|2 years (2019-01-15)||217.18%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||9.8|
Valuing Salarius Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Salarius Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Salarius Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Salarius Pharmaceuticals shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$4.8 million|
|Gross profit TTM||USD$-553,896|
|Return on assets TTM||-19.92%|
|Return on equity TTM||-49.22%|
|Market capitalisation||USD$21.5 million|
TTM: trailing 12 months
There are currently 585,014 Salarius Pharmaceuticals shares held short by investors – that's known as Salarius Pharmaceuticals's "short interest". This figure is 3% up from 567,997 last month.
There are a few different ways that this level of interest in shorting Salarius Pharmaceuticals shares can be evaluated.
Salarius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Salarius Pharmaceuticals shares currently shorted divided by the average quantity of Salarius Pharmaceuticals shares traded daily (recently around 130875.61521253). Salarius Pharmaceuticals's SIR currently stands at 4.47. In other words for every 100,000 Salarius Pharmaceuticals shares traded daily on the market, roughly 4470 shares are currently held short.
However Salarius Pharmaceuticals's short interest can also be evaluated against the total number of Salarius Pharmaceuticals shares, or, against the total number of tradable Salarius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Salarius Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Salarius Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0303% of the tradable shares (for every 100,000 tradable Salarius Pharmaceuticals shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Salarius Pharmaceuticals.
Find out more about how you can short Salarius Pharmaceuticals stock.
We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.
Salarius Pharmaceuticals's shares were split on a 1:25 basis on 22 July 2019. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.